NASDAQ:GANX Gain Therapeutics (GANX) Stock Price, News & Analysis $1.82 +0.06 (+3.64%) As of 01:01 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC Filings About Gain Therapeutics Stock (NASDAQ:GANX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Gain Therapeutics alerts:Sign Up Key Stats Today's Range$1.78▼$1.8350-Day Range$1.63▼$2.1652-Week Range$1.53▼$4.34Volume142,060 shsAverage Volume740,322 shsMarket Capitalization$79.61 millionP/E RatioN/ADividend YieldN/APrice Target$7.50Consensus RatingModerate Buy Company Overview Gain Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing small-molecule therapies for neurodegenerative diseases and lysosomal storage disorders. The company’s research is directed at restoring the function of misfolded or dysfunctional proteins that contribute to disease progression. Gain Therapeutics uses its proprietary SEE-Tx drug-discovery platform to identify previously unrecognized allosteric binding sites on proteins and develop compounds designed to stabilize or reactivate those proteins. Its lead program, GT-02287, is an orally administered small molecule being studied for Parkinson’s disease, including disease associated with mutations in the GBA1 gene. The company was founded in 2017 and has pursued development through clinical-stage programs supported by preclinical research in neurodegenerative disease. Gain Therapeutics is headquartered in the United States and trades on the Nasdaq Capital Market under the symbol GANX.AI Generated. May Contain Errors. Read More Gain Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks53rd Percentile Overall ScoreGANX MarketRank™: Gain Therapeutics scored higher than 53% of companies evaluated by MarketBeat, and ranked 444th out of 895 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.9 / 5Analyst RatingModerate Buy Consensus RatingGain Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on no strong buy ratings, 5 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialGain Therapeutics has a consensus price target of $7.50, representing about 313.2% upside from its current price of $1.82.Amount of Analyst CoverageGain Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Gain Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Gain Therapeutics are expected to decrease in the coming year, from ($0.50) to ($0.55) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Gain Therapeutics is -3.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Gain Therapeutics is -3.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGain Therapeutics has a P/B Ratio of 3.78. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Gain Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted6.68% of the float of Gain Therapeutics has been sold short.Short Interest Ratio / Days to CoverGain Therapeutics has a short interest ratio ("days to cover") of 7.65.Change versus previous monthShort interest in Gain Therapeutics has recently decreased by 5.30%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGain Therapeutics does not currently pay a dividend.Dividend GrowthGain Therapeutics does not have a long track record of dividend growth. News and Social Media3.1 / 5News Sentiment1.00 News SentimentGain Therapeutics has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Gain Therapeutics this week, compared to 3 articles on an average week.Search Interest4 people have searched for GANX on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Gain Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Gain Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders4.15% of the stock of Gain Therapeutics is held by insiders.Percentage Held by Institutions11.97% of the stock of Gain Therapeutics is held by institutions.Read more about Gain Therapeutics' insider trading history. Receive GANX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Gain Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GANX Stock News HeadlinesGain Therapeutics Announces CEO Gene Mack to Participate in ROTH Healthcare Opportunities Conference Panel and One-on-One MeetingsSeptember 17, 2026 | quiverquant.comQGain Therapeutics to Participate at ROTH Fifth Annual Healthcare Opportunities ConferenceSeptember 17, 2026 | globenewswire.comThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.September 21 at 1:00 AM | Chaikin Analytics (Ad)Gain Therapeutics to Participate at H.C. Wainwright 28th Annual Global Investment ConferenceAugust 25, 2026 | globenewswire.comGain Therapeutics IncAugust 12, 2026 | money.usnews.comGain Therapeutics Reports Financial Results for Second Quarter 2026 and Provides Corporate UpdateAugust 11, 2026 | markets.businessinsider.comGain Therapeutics CEO Gene Mack Issues Letter to Shareholders and Provides Operational UpdateJuly 16, 2026 | globenewswire.comGain Therapeutics advances GT-02287 into Phase 2 Parkinson’s trialJune 30, 2026 | theglobeandmail.comSee More Headlines GANX Stock Analysis - Frequently Asked Questions How have GANX shares performed this year? Gain Therapeutics' stock was trading at $3.22 at the beginning of the year. Since then, GANX shares have decreased by 43.6% and is now trading at $1.8150. How were Gain Therapeutics' earnings last quarter? Gain Therapeutics, Inc. (NASDAQ:GANX) issued its earnings results on Tuesday, August, 11th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.14) by $0.03. When did Gain Therapeutics IPO? Gain Therapeutics (GANX) raised $40 million in an IPO on Thursday, March 18th 2021. The company issued 3,636,364 shares at a price of $10.00-$12.00 per share. BTIG and Oppenheimer & Co,. acted as the underwriters for the IPO and National Securities Corp. was co-manager. Who are Gain Therapeutics' major shareholders? Top institutional investors of Gain Therapeutics include GSA Capital Partners LLP (1.48%), BlackRock Inc. (0.64%), Squarepoint Ops LLC (0.31%) and HighTower Advisors LLC (0.04%). Insiders that own company stock include Eric I Richman, Khalid Islam, Jeffrey Scott Riley, Gene Mack and Matthias Alder. View institutional ownership trends. How do I buy shares of Gain Therapeutics? Shares of GANX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Gain Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Gain Therapeutics investors own include PayPal (PYPL), Pfizer (PFE), SEA (SE), Taiwan Semiconductor Manufacturing (TSM), ZIM Integrated Shipping Services (ZIM), ADC Therapeutics (ADCT) and Avino Silver & Gold Mines (ASM). Company Calendar Last Earnings8/11/2026Today9/21/2026Next Earnings (Estimated)11/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (6m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 GANX's financial health is in the Yellow zone, according to TradeSmith. GANX has been in this zone for over 6 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:GANX CIK1819411 Webwww.gaintherapeutics.com Phone301-500-1556FaxN/AEmployees21Year Founded2017Price Target and Rating Average Price Target for Gain Therapeutics$7.50 High Price Target$10.00 Low Price Target$5.00 Potential Upside/Downside+313.2%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($0.50) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$20.16 million Net MarginsN/A Pretax MarginN/A Return on Equity-161.59% Return on Assets-118.36% Debt Debt-to-Equity Ratio0.02 Current Ratio4.36 Quick Ratio4.36 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.48 per share Price / Book3.78Miscellaneous Outstanding Shares43,644,000Free Float41,833,000Market Cap$79.21 million OptionableOptionable Beta0.20 Social Links 10 Best Stocks to Own - Fall 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Fall 2026, despite the economic uncertainty rattling markets right now. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free Report This page (NASDAQ:GANX) was last updated on 9/21/2026 by MarketBeat.com Staff. From Our PartnersTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredMILLIONAIRE MASTERCLASS INVITE: AltucherJames Altucher says Elon Musk is preparing an unprecedented project set to surface on September 25. Altuche...Paradigm Press | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gain Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gain Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
